SIREN : 328297841
PANPHARMA is a French company founded 42 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LUITRE-DOMPIERRE (35133), this company of category ETI shows in 2024 a revenue of 104.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 104 495 158 € | 93 909 571 € | 89 792 953 € | 91 997 736 € | 106 334 288 € | 78 944 222 € | 87 004 200 € | 91 726 736 € | 87 641 573 € |
| Net income | 3 150 979 € | 1 647 112 € | 3 789 401 € | 7 055 982 € | 13 203 491 € | 2 880 909 € | 1 991 125 € | 4 417 268 € | 1 165 097 € |
| EBITDA | 9 097 340 € | 3 872 588 € | 6 310 034 € | 12 079 047 € | 23 124 641 € | 5 667 187 € | 6 434 368 € | 13 381 123 € | 3 468 123 € |
| Net margin | 3.0% | 1.8% | 4.2% | 7.7% | 12.4% | 3.6% | 2.3% | 4.8% | 1.3% |
In 2024, PANPHARMA achieves revenue of 104.5 M€. Revenue is growing positively over 9 years (CAGR: +2.2%). Vs 2023, growth of +11% (93.9 M€ -> 104.5 M€). After deducting consumption (54.6 M€), gross margin stands at 49.9 M€, i.e. a rate of 48%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 9.1 M€, representing 8.7% of revenue. Positive scissor effect: EBITDA margin improves by +4.6 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 3.2 M€, i.e. 3.0% of revenue. This profit can be retained or distributed to shareholders.
104 495 158 €
49 937 466 €
9 097 340 €
4 681 775 €
3 150 979 €
8.7%
The debt ratio (= Financial debt / Equity x 100) stands at 71%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 8.6 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 4.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
71.046%
44.013%
4.629%
8.626
59.6%
In 2024, the debt ratio of PANPHARMA (71.05) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of PANPHARMA (44.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of PANPHARMA (8.63) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 245.97. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 8.7x. Operating income very largely covers interest expenses: high safety margin.
245.973
8.732
In 2024, the liquidity ratio of PANPHARMA (245.97) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of PANPHARMA (8.7x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 76 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 88 days. Favorable situation: supplier credit is longer than customer credit by 12 days. Inventory turnover is 70 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 124 days of revenue, i.e. 36.1 M€ to permanently finance.
36 088 448 €
76 j
88 j
70 j
124 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 628 681€ to 1 932 319€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PANPHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of PANPHARMA in 2024 is 104.5 M€.
Yes, PANPHARMA generated a net profit of 3.2 M€ in 2024.
The headquarters of PANPHARMA is located in LUITRE-DOMPIERRE (35133), in the department Ille-et-Vilaine.
The tax return of PANPHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PANPHARMA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.